Offering an investigational medication like retatrutide outside of approved regulatory pathways is not the same as dispensing an approved medication like semaglutide and tirzepatice
Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ (2017) Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
As a result, the function of vagal afferent neurons is impaired, the interoceptive signal received by the brain is weakened and hippocampal function declines
The clinical significance of this is unclear
Neuroinflammation, Alzheimers, and Cognition Neuroinflammation, Alzheimers, and Cognition Emerging research is also showing promise for GLP-1 drugs in treatment of neurodegenerative diseases
Find articles by Miz, K